* If you want to update the article please login/register
We report the outcomes of the PEMDAC phase 2 scientific test where the HDAC prevention entinostat was incorporated with the PD-1 prevention pembrolizumab in patients with metastatic uveal melanoma. Goal responses and/or prolonged survival were seen in patients with BAP1 wildtype growths, and in one person with an iris melanoma that showed a UV signature. Longer survival correlated with reduced baseline ctDNA degrees or LDH. To conclude, HDAC restraint and anti-PD1 immunotherapy causes long lasting responses in a part of patients with metastatic.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions